These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16531989)

  • 1. Entry order as a consideration for innovation strategies.
    Cohen FJ
    Nat Rev Drug Discov; 2006 Apr; 5(4):285-93. PubMed ID: 16531989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Price regulation and generic competition in the pharmaceutical market.
    Dalen DM; Strøm S; Haabeth T
    Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical.
    Kong Y
    Health Econ; 2009 May; 18(5):591-606. PubMed ID: 18816580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In need of treatment? Merger control, pharmaceutical innovation, and consumer welfare.
    Ben-Asher D; Juris M
    J Leg Med; 2000 Sep; 21(3):271-349. PubMed ID: 11055154
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach.
    Augurzky B; Göhlmann S; Gress S; Wasem J
    Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No immediate pain relief for the pharmaceutical industry.
    Ahlborn H; Henderson S; Davies N
    Curr Opin Drug Discov Devel; 2005 May; 8(3):384-91. PubMed ID: 15892254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The economic impact of the pharmaceutical and medical technology industry in New Jersey.
    Tremayne WH
    N J Med; 2000 Aug; 97(8):49-50. PubMed ID: 10959176
    [No Abstract]   [Full Text] [Related]  

  • 8. The impact of generic substitution on price competition in Finland.
    Aalto-Setälä V
    Eur J Health Econ; 2008 May; 9(2):185-91. PubMed ID: 17508226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economics of new oncology drug development.
    DiMasi JA; Grabowski HG
    J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folly or volley? Will a dollar $4 pill finally open the healthcare market to competitive pricing?
    Sturm AC
    Healthc Financ Manage; 2006 Nov; 60(11):120-2. PubMed ID: 17094287
    [No Abstract]   [Full Text] [Related]  

  • 11. The state of innovation in drug development.
    Kola I
    Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
    Federsel HJ
    Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Funding pharmaceutical innovation through direct tax credits.
    Lybecker KM; Freeman RA
    Health Econ Policy Law; 2007 Jul; 2(Pt 3):267-84. PubMed ID: 18634650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The London Agreement and the future of parallel imports.
    Muir J
    Nat Biotechnol; 2008 Aug; 26(8):877-9. PubMed ID: 18688237
    [No Abstract]   [Full Text] [Related]  

  • 15. The pharmaceutical industry--to whom is it accountable?
    Rightor N
    N Engl J Med; 2000 Nov; 343(19):1416; discussion 1417. PubMed ID: 11183882
    [No Abstract]   [Full Text] [Related]  

  • 16. The market and medical innovation: human passions and medical advancement.
    Cherry MJ
    J Med Philos; 2005 Dec; 30(6):555-69. PubMed ID: 16396784
    [No Abstract]   [Full Text] [Related]  

  • 17. Entry time effects and follow-on drug competition.
    Andrade LF; Sermet C; Pichetti S
    Eur J Health Econ; 2016 Jan; 17(1):45-60. PubMed ID: 25501258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Competition Commission identifies issues for further consideration.
    Vet Rec; 2002 Apr; 150(16):494-6. PubMed ID: 12017523
    [No Abstract]   [Full Text] [Related]  

  • 19. Big pharma swallows biotech's pride.
    Huggett B
    Nat Biotechnol; 2008 Sep; 26(9):955-6. PubMed ID: 18779785
    [No Abstract]   [Full Text] [Related]  

  • 20. Realizing two-tiered innovation policy through drug regulation.
    Ridgway WE
    Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.